Brain Tumor Drugs Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	181 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19260690

Best Price Guarantee
Price	from $4,850
Length	181 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19260690

Brain Tumor Drugs Market

Growth Factors of Brain Tumor Drugs Market

The brain tumor drugs market size was valued at USD 1.80 billion in 2022, and the market is now projected to grow from USD 1.89 billion in 2023 to USD 3.72 billion by 2030, exhibiting a CAGR of 10.2% during the forecast period of 2023-2030.

The brain tumor drugs market growth is relatively slow due to the effects of COVID-19 which offered lower chances of diagnosis and treatment. Constrained utilization of healthcare services occurred with an 11% lowered occurrence of cancer in 2020 compared to 2019 in many forms of cancer examination. Other factors, beyond the manufacturing and distribution network, remained important for players such as F. Hoffmann-La Roche Ltd, as the revenue splits of Avastin decreased to 29.4% in 2020. As a result, season-wise data showed that the sale of medicines had reduced throughout the year 2021 and one of the reasons for this phenomenon was the stocking up of medicines.

The brain tumor drugs market share has been expected to grow due to the rise in the Geritol population and because people have unhealthy lifestyles and the occurrences of cancer stem cells in the brain have also risen. This research also shows that brain tumors are a type of cancer and account for 1-2% of total cancer incidences, nonetheless, this type has high mortality rates when caused by radiation. For instance, the incidences have been increasing in North America and Asia Pacific, thereby increasing support for treatment innovation. In the U.S., it was estimated that 24,530 of the occurrences took place in 2021. An increase in research and development budgets and advancing government backing are also responsible for the growth in the brain tumor drug market.

Additionally, advancements in diagnostic methods are improving brain tumor detection, despite challenges such as the blood-brain barrier that limits chemotherapy effectiveness. Predictive biomarkers and genetic analysis techniques, such as liquid biopsies and molecular methods such as ddPCR, help refine diagnosis and treatment. These innovations, including blood-based detection tests, boost early diagnosis rates and support the adoption of brain tumor drugs. Enhanced detection methods also drive personalized medicine development and improve patient survival rates.

Comprehensive Analysis of Brain Tumor Drugs Market

The brain tumor drugs market and healthcare industry are rising exponentially due to their market segmentation. This market expansion effectively provides detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by therapy, by indication and by distribution channel. The therapy includes, Targeted Therapy, Chemotherapy, Immunotherapy and Others. The indication includes, Pituitary, Meningioma, Glioma and Others. The distribution channel includes, Hospital Pharmacy and Retail & Online Pharmacy.

North America emerged as the largest market as it generated USD 0.79 billion in 2022 and held a 43.88% share in revenue. This is because of better reimbursement policies in the U.S. and the fact that new drugs join market streams only in their mature stages. Also, the company secured FDA approval for a biosimilar known as ALYMSYS which is employed for managing some forms of cancer including recurrent glioblastoma in April 2022. These factors have promoted development in the region's markets.

Leading companies provide vital input in the healthcare sector, assure the growth of industrial prospectus, and define market standards. These players include, F. Hoffmann-La Roche Ltd (U.S.), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), NextSource Pharmaceuticals, LLC (U.S.) and Emcure Pharmaceuticals (India). These market players provide a level-playing competitive landscape.

In September 2022, F. Hoffmann-La Roche Ltd. plans to acquire Good Therapeutics. Thus, the idea was to obtain rights to The Good Therapeutics’ platform technology, which was potentially effective in various spheres, including cancer, metabolic, autoimmune, and other medical areas, as well as pain management.

Segmentation Table

Global Brain Tumor Drugs Market Scope

Study Period 2019-2030

Base Year 2022

Forecast Period 2023-2030

Growth Rate CAGR of 10.2% from 2023-2030

Historical Period 2019-2021

Unit Value (USD Billion)

Segmentation By Therapy, Indication, Distribution Channel, and Region

By Therapy Targeted Therapy

Chemotherapy

Immunotherapy

Others

By Indication Pituitary

Meningioma

Glioma

Others

By Distribution Channel Hospital Pharmacy

Retail & Online Pharmacy

By Region North America (By Therapy, By Indication, By Distribution Channel, and By Country)

U.S. (By Indication)
Canada (By Indication)

Europe (By Therapy, By Indication, By Distribution Channel, and By Country)

U.K. (By Indication)
Germany (By Indication)
France (By Indication)
Italy (By Indication)
Spain (By Indication)
Rest of Europe (By Indication)

Asia Pacific (By Therapy, By Indication, By Distribution Channel, and By Country)

China (By Indication)
Japan (By Indication)
India (By Indication)
Australia (By Indication)
Southeast Asia (By Indication)
Rest of Asia Pacific (By Indication)

Latin America (By Therapy, By Indication, By Distribution Channel, and By Country)

Brazil (By Indication)
Mexico (By Indication)
Rest of Latin America (By Indication)

Middle East and Africa (By Therapy, By Indication, By Distribution Channel, and By Country)

GCC (By Indication)
South Africa (By Indication)
Rest of Middle East & Africa (By Indication)

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Incidence of Brain Cancer, Key Region, 2020/2021; 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions; 4.3. Overview of the Regulatory Scenario by Key Region/Countries; 4.4. New Product Launches by Key Players; 4.5. Impact of COVID-19 on Brain Tumor Drugs Market
5. Global Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 5.1. Market Analysis, Insights and Forecast – By Therapy; 5.1.1. Targeted Therapy; 5.1.2. Chemotherapy; 5.1.3. Immunotherapy; 5.1.4. Others; 5.2. Market Analysis, Insights and Forecast – By Indication; 5.2.1. Pituitary Tumors; 5.2.2. Meningioma; 5.2.3. Glioblastoma; 5.2.4. Others; 5.3. Market Analysis, Insights and Forecast – By Distribution Channel; 5.3.1. Hospital Pharmacy; 5.3.2. Retail & Online Pharmacy; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 6.1. Market Analysis, Insights and Forecast – By Therapy; 6.1.1. Targeted Therapy; 6.1.2. Chemotherapy; 6.1.3. Immunotherapy; 6.1.4. Others; 6.2. Market Analysis, Insights and Forecast – By Indication; 6.2.1. Pituitary Tumors; 6.2.2. Meningioma; 6.2.3. Glioblastoma; 6.2.4. Others; 6.3. Market Analysis, Insights and Forecast – By Distribution Channel; 6.3.1. Hospital Pharmacy; 6.3.2. Retail & Online Pharmacy; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.1.1. By Indication; 6.4.2. Canada; 6.4.2.1. By Indication
7. Europe Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 7.1. Market Analysis, Insights and Forecast – By Therapy; 7.1.1. Targeted Therapy; 7.1.2. Chemotherapy; 7.1.3. Immunotherapy; 7.1.4. Others; 7.2. Market Analysis, Insights and Forecast – By Indication; 7.2.1. Pituitary Tumors; 7.2.2. Meningioma; 7.2.3. Glioblastoma; 7.2.4. Others; 7.3. Market Analysis, Insights and Forecast – By Distribution Channel; 7.3.1. Hospital Pharmacy; 7.3.2. Retail & Online Pharmacy; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.4.1. Germany; 7.4.1.1. By Indication; 7.4.2. U.K.; 7.4.2.1. By Indication; 7.4.3. France; 7.4.3.1. By Indication; 7.4.4. Spain; 7.4.4.1. By Indication; 7.4.5. Italy; 7.4.5.1. By Indication; 7.4.6. Scandinavia; 7.4.6.1. By Indication; 7.4.7. Rest of Europe; 7.4.7.1. By Indication
8. Asia Pacific Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 8.1. Market Analysis, Insights and Forecast – By Therapy; 8.1.1. Targeted Therapy; 8.1.2. Chemotherapy; 8.1.3. Immunotherapy; 8.1.4. Others; 8.2. Market Analysis, Insights and Forecast – By Indication; 8.2.1. Pituitary Tumors; 8.2.2. Meningioma; 8.2.3. Glioblastoma; 8.2.4. Others; 8.3. Market Analysis, Insights and Forecast – By Distribution Channel; 8.3.1. Hospital Pharmacy; 8.3.2. Retail & Online Pharmacy; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.4.1. Japan; 8.4.1.1. By Indication; 8.4.2. China; 8.4.2.1. By Indication; 8.4.3. India; 8.4.3.1. By Indication; 8.4.4. Australia; 8.4.4.1. By Indication; 8.4.5. Southeast Asia; 8.4.5.1. By Indication; 8.4.6. Rest of Asia Pacific; 8.4.6.1. By Indication
9. Latin America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 9.1. Market Analysis, Insights and Forecast – By Therapy; 9.1.1. Targeted Therapy; 9.1.2. Chemotherapy; 9.1.3. Immunotherapy; 9.1.4. Others; 9.2. Market Analysis, Insights and Forecast – By Indication; 9.2.1. Pituitary Tumors; 9.2.2. Meningioma; 9.2.3. Glioblastoma; 9.2.4. Others; 9.3. Market Analysis, Insights and Forecast – By Distribution Channel; 9.3.1. Hospital Pharmacy; 9.3.2. Retail & Online Pharmacy; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.4.1. Brazil; 9.4.1.1. By Indication; 9.4.2. Mexico; 9.4.2.1. By Indication; 9.4.3. Rest of Latin America; 9.4.3.1. By Indication
10. Middle East & Africa Brain Tumor Drugs Market Analysis, Insights and Forecast, 2019-2030: 10.1. Market Analysis, Insights and Forecast – By Therapy; 10.1.1. Targeted Therapy; 10.1.2. Chemotherapy; 10.1.3. Immunotherapy; 10.1.4. Others; 10.2. Market Analysis, Insights and Forecast – By Indication; 10.2.1. Pituitary Tumors; 10.2.2. Meningioma; 10.2.3. Glioblastoma; 10.2.4. Others; 10.3. Market Analysis, Insights and Forecast – By Distribution Channel; 10.3.1. Hospital Pharmacy; 10.3.2. Retail & Online Pharmacy; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.4.1. GCC; 10.4.1.1. By Indication; 10.4.2. South Africa; 10.4.2.1. By Indication; 10.4.3. Rest of Middle East & Africa; 10.4.3.1. By Indication
11. Competitive Analysis: 11.1. Global Market Share Analysis (2022); 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability)); 11.2.1. Pfizer Inc.; 11.2.1.1. Overview,; 11.2.1.2. Product,; 11.2.1.3. SWOT Analysis,; 11.2.1.4. Recent Developments,; 11.2.1.5. Strategies,; 11.2.1.6. financials (Based on Availability); 11.2.2. F. Hoffmann-La Roche Ltd; 11.2.2.1. Overview,; 11.2.2.2. Product,; 11.2.2.3. SWOT Analysis,; 11.2.2.4. Recent Developments,; 11.2.2.5. Strategies,; 11.2.2.6. financials (Based on Availability); 11.2.3. Novartis AG; 11.2.3.1. Overview,; 11.2.3.2. Product,; 11.2.3.3. SWOT Analysis,; 11.2.3.4. Recent Developments,; 11.2.3.5. Strategies,; 11.2.3.6. financials (Based on Availability); 11.2.4. Merck & Co. Inc.; 11.2.4.1. Overview,; 11.2.4.2. Product,; 11.2.4.3. SWOT Analysis,; 11.2.4.4. Recent Developments,; 11.2.4.5. Strategies,; 11.2.4.6. financials (Based on Availability); 11.2.5. Amneal Pharmaceuticals LLC.; 11.2.5.1. Overview,; 11.2.5.2. Product,; 11.2.5.3. SWOT Analysis,; 11.2.5.4. Recent Developments,; 11.2.5.5. Strategies,; 11.2.5.6. financials (Based on Availability); 11.2.6. Amgen Inc.; 11.2.6.1. Overview,; 11.2.6.2. Product,; 11.2.6.3. SWOT Analysis,; 11.2.6.4. Recent Developments,; 11.2.6.5. Strategies,; 11.2.6.6. financials (Based on Availability); 11.2.7. NextSource Pharmaceuticals, LLC; 11.2.7.1. Overview,; 11.2.7.2. Product,; 11.2.7.3. SWOT Analysis,; 11.2.7.4. Recent Developments,; 11.2.7.5. Strategies,; 11.2.7.6. financials (Based on Availability); 11.2.8. Emcure Pharmaceuticals; 11.2.8.1. Overview,; 11.2.8.2. Product,; 11.2.8.3. SWOT Analysis,; 11.2.8.4. Recent Developments,; 11.2.8.5. Strategies,; 11.2.8.6. financials (Based on Availability)